In 2026, liquid biopsy, biomarker science, and diagnostics are advancing towards generating clinically meaningful, operationally scalable data for real-world impact. Brad Evans, PhD, Sr. Scientific Advisor, breaks down what this shift means:
hubs.ly/Q04kF27z0